<DOC>
	<DOCNO>NCT00750581</DOCNO>
	<brief_summary>A large patent ductus arteriosus ( PDA ) associate congestive heart failure , pulmonary hemorrhage , chronic lung disease ( CLD ) , necrotizing enterocolitis ( NEC ) intraventricular bleeding . Indomethacin first line treatment PDA . Failure ductal closure first course indomethacin report 30-40 % infant , high failure rate infant weigh &lt; 1000 gm . PDA ligation associate early postoperative hypotension , oxygenation failure adverse neurodevelopmental outcome preterm infant . The use escalate dos Indomethacin treatment persistent PDA find safe decreased need PDA ligation without adverse effect one observational study.We hypothesize use escalate dose intravenous indomethacin result increase probability survival without need surgical ligation PDA compare standard dose indomethacin newborn infant &lt; 29 week gestational age persistent PDA .</brief_summary>
	<brief_title>An Escalating Dose Indomethacin Treatment Persistent Patent Ductus Arteriosus ( PDA ) In Preterm Infants</brief_title>
	<detailed_description>This study randomize control trial.Those eligible infant randomize either Standard Dose group Escalating Dose indomethacin group obtain parental consent . The infant randomize standard dose group receive indomethacin ( 0.1 mg/kg ) 24 hr interval 5 day . Escalating Dose group infant receive indomethacin ( 0.2 mg/kg/dose ) 12 hr interval 2 dos , follow indomethacin ( 0.3 mg/kg/dose ) 12 hr interval 2 dos , Indomethacin ( 0.4 mg/kg/dose ) 12 hr interval 2 dos , increase indomethacin ( 0.5 mg/kg/dose ) 12 hour interval 2 dos finally indomethacin 0.6 mg/kg/dose 12 hourly interval 2 dos . To keep study blind , standard group receive 5 extra dos normal saline infusion similar volume 12 hrly interval indomethacin schedule match Escalating dose Indomethacin Schedule . Daily Echo perform Echo show closure PDA 3 day assign treatment , indomethacin give group .</detailed_description>
	<mesh_term>Ductus Arteriosus , Patent</mesh_term>
	<mesh_term>Indomethacin</mesh_term>
	<criteria>Preterm infant gestational age &lt; 29 week and/or birth weight &lt; 1251gm Presence PDA completion first course indomethacin Infants PDA dependent congenital heart disease Chromosomal major congenital anomaly Infants use indomethacin contraindicate . ( i.e.infants acute renal failure , necrotizing enterocolitis , severe thrombocytopenia ( platelet count &lt; 60,000/ mm3 ) evidence clinical bleeding ( pulmonary bleeding , severe intraventricular bleeding grade 3 &amp; 4 )</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>4 Weeks</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Patent Ductus Arteriosus</keyword>
</DOC>